407 related articles for article (PubMed ID: 31179485)
1. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
[TBL] [Abstract][Full Text] [Related]
3. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
4. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
5. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
6. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
[TBL] [Abstract][Full Text] [Related]
11. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
12. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
[TBL] [Abstract][Full Text] [Related]
13. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
[TBL] [Abstract][Full Text] [Related]
15. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
Alsumali A; Chemaly RF; Graham J; Jiang Y; Merchant S; Miles L; Schelfhout J; Yang J; Tang Y
J Med Virol; 2021 Jun; 93(6):3786-3794. PubMed ID: 32844453
[TBL] [Abstract][Full Text] [Related]
17. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
19. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
[TBL] [Abstract][Full Text] [Related]
20. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]